UBS Group AG trimmed its holdings in shares of Aptevo Therapeutics Inc (NASDAQ:APVO) by 13.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,015 shares of the biotechnology company’s stock after selling 1,533 shares during the period. UBS Group AG owned approximately 0.31% of Aptevo Therapeutics worth $83,000 at the end of the most recent reporting period.

Separately, Marshall Wace LLP acquired a new position in Aptevo Therapeutics during the first quarter worth about $33,000. Hedge funds and other institutional investors own 19.57% of the company’s stock.

NASDAQ:APVO opened at $8.04 on Thursday. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.33. Aptevo Therapeutics Inc has a 1-year low of $2.94 and a 1-year high of $11.73. The firm has a market capitalization of $25.99 million, a price-to-earnings ratio of -0.53 and a beta of 2.56. The stock has a fifty day simple moving average of $8.17 and a 200 day simple moving average of $5.71.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($2.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.27) by $0.17. Aptevo Therapeutics had a negative return on equity of 265.88% and a negative net margin of 86.42%. The business had revenue of $0.47 million during the quarter, compared to analyst estimates of $0.29 million. Equities analysts predict that Aptevo Therapeutics Inc will post -8.61 earnings per share for the current year.

A number of research firms recently issued reports on APVO. Zacks Investment Research raised Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 target price on the stock in a report on Tuesday, August 11th. Piper Sandler increased their price target on Aptevo Therapeutics from $24.00 to $32.00 in a research report on Friday, August 14th.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.

Featured Story: Price-Sales Ratio

Want to see what other hedge funds are holding APVO? Visit to get the latest 13F filings and insider trades for Aptevo Therapeutics Inc (NASDAQ:APVO).

Institutional Ownership by Quarter for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with's FREE daily email newsletter.